Anzeige
Mehr »
Freitag, 19.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ETBY | ISIN: US68270C1036 | Ticker-Symbol:
NASDAQ
18.09.25 | 16:30
0,878 US-Dollar
-1,47 % -0,013
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ONEMEDNET CORP Chart 1 Jahr
5-Tage-Chart
ONEMEDNET CORP 5-Tage-Chart
GlobeNewswire (Europe)
220 Leser
Artikel bewerten:
(1)

OneMedNet Corporation: OneMedNet Regains Compliance with NASDAQ Listing Requirements

MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet" or the "Company"), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data ("iRWD"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(b)(2) (the "Rule") after the market value of the Company's common stock exceeded $35,000,000 for 10 consecutive business days. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") confirming compliance with the Rule. As a result, the Company has cleared all listing deficiency notices issued by Nasdaq.

Aaron Green, Chief Executive Officer, stated, "We are pleased to have now achieved compliance with the Nasdaq listing rules. This accomplishment will enable us to focus in 2025 on growing our revenue and business operations."

During the 2024 and 2025, we developed and started to execute on our strategic plan by:

  • Expanding its product offerings, which now include data masking solutions for additional industries and subscription-based offerings for the Company's healthcare and real-world data solutions.
  • Appointing Bob Golden as Chief Financial Officer to oversee enhancements in the Company's financial reporting processes.
  • Hiring a Director of Business Development, Margaret Nash, and Vice President of Marketing, Michael Wong, to continue to build our commercial presence with Life Science organizations, additionally recently signing an agreement with Bayer's AI Innovation Platform (AIIP) announced in early December 2024.
  • Enhancing our Data De-Identification and curation service leveraging Generative AI and deploying OneMedNet's 2.0 generation indexer OMNi, to improve the speed and accuracy of data searching and indexing.
  • Refreshing the composition of the Company's Board of Directors with three new directors who have relevant industry, financial and public company expertise.
  • Improving liquidity by raising approximately $6.4M in private placements with Off the Chain Capital and an affiliate of Discovery Capital Management.
  • Enhancing treasury management with a Bitcoin on the balance sheet strategy.

OneMedNet is now in a position to take advantage of the growing Real World Data market with a meaningful market share.

About OneMedNet Corporation

OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data ("RWD") repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD network. OneMedNet's proprietary iRWD platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, ECGs, EEGs, prescriptions, physician notes, laboratory results, and uniquely, medical imaging. Employing its robust iRWD platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.

OneMedNet's platform is designed to address diverse clinical requirements across various domains, such as rare diseases, central nervous system disorders, oncology, cardiology and women's health. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet's strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

OneMedNet Contacts:

Michael Wong, VP Marketing
Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION


© 2025 GlobeNewswire (Europe)
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.